idh1- or idh2-mutant grade 2 astrocytoma or oligodendroglioma FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 1 idh1- or idh2-mutant grade 2 astrocytoma or oligodendroglioma drug. 1 FDA approval recorded, most recently INDIGO (vorasidenib) on Aug 2024.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| INDIGO (vorasidenib) | ZBIO | small_molecule | — |
Upcoming catalysts
No events in this view.
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Aug 2024Month disclosed | INDIGO (vorasidenib) | NUVB | FDA approval | IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma | Approved | SEC 8-K Exhibit 99.1 |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.
Questions
What idh1- or idh2-mutant grade 2 astrocytoma or oligodendroglioma drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.